🇪🇺 arginine/lysine in European Union

EMA authorised arginine/lysine on 25 July 2019

Marketing authorisation

EMA — authorised 25 July 2019

  • Application: EMEA/H/C/004541
  • Marketing authorisation holder: Advanced Accelerator Applications
  • Local brand name: LysaKare
  • Indication: LysaKare is indicated for reduction of renal radiation exposure during Peptide-Receptor Radionuclide Therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.
  • Status: approved

Read official source →

Other Immunology approved in European Union

Frequently asked questions

Is arginine/lysine approved in European Union?

Yes. EMA authorised it on 25 July 2019.

Who is the marketing authorisation holder for arginine/lysine in European Union?

Advanced Accelerator Applications holds the EU marketing authorisation.